Drug Profile
Research programme: cancer therapy - CEPTYR
Alternative Names: CEPTYR 234; PTPx inhibitor; PTPxx; PTPyLatest Information Update: 09 Jul 2007
Price :
$50
*
At a glance
- Originator CEPTYR
- Class
- Mechanism of Action Protein-tyrosine-phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Jul 2004 Compounds from this research programme are available for licensing (http://www.ceptyr.com)
- 30 Jul 2003 Preclinical development for Cancer in USA (unspecified route)